Inventor
POURDEHNAD MICHAEL
US18 patents
⚠️ This page may combine multiple inventors who share the name “POURDEHNAD MICHAEL”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CELGENE CORP
17 patentsUS9499514B2Nov 22, 2016
Antiproliferative compounds and methods of use thereof
CELGENE CORP28 citations93
US9968596B2May 15, 2018
Antiproliferative compounds and methods of use thereof
CELGENE CORP8 citations82
US9808451B2Nov 7, 2017
Antiproliferative compounds and methods of use thereof
CELGENE CORP12 citations82
US10245258B2Apr 2, 2019
Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
CELGENE CORP8 citations80
US11241423B2Feb 8, 2022
Antiproliferative compounds and methods of use thereof
CELGENE CORP2 citations72
US11666579B2Jun 6, 2023
Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
CELGENE CORP2 citations71
US10689708B2Jun 23, 2020
Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs
CELGENE CORP3 citations67
US10973822B2Apr 13, 2021
Combination therapy for treatment of hematological cancers and solid tumors
CELGENE CORP3 citations66
US12178822B2Dec 31, 2024
Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dion
CELGENE CORP0 citations60
US12103923B2Oct 1, 2024
Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
CELGENE CORP0 citations60
US11390617B2Jul 19, 2022
Methods of treating non-Hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
CELGENE CORP1 citations60
US11590117B2Feb 28, 2023
Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
CELGENE CORP0 citations59
US12396995B2Aug 26, 2025
Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use
CELGENE CORP0 citations57
US11628172B2Apr 18, 2023
Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
CELGENE CORP1 citations57
US11583536B2Feb 21, 2023
Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use
CELGENE CORP0 citations57
US12090147B2Sep 17, 2024
Combination therapy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
CELGENE CORP0 citations53
US10159675B2Dec 25, 2018
Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione
CELGENE CORP0 citations48